Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Primary Myelofibrosis 12Polycythemia Vera 11Myelodysplastic Syndromes 10Leukemia 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Myeloproliferative Disorders 8Recurrence 6Leukemia, Myelomonocytic, Chronic 6Hematologic Neoplasms 6Breast Neoplasms 6Myelodysplastic-Myeloproliferative Diseases 5Lymphoma, T-Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Graft vs Host Disease 5Thrombocythemia, Essential 4Leukemia, Myeloid, Chronic-Phase 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Prolymphocytic, T-Cell 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2

Interventions

fludarabine phosphate 21Cyclophosphamide 20Peripheral Blood Stem Cell Transplantation 19Busulfan 16Tacrolimus 14Whole-Body Irradiation 12Methotrexate 12Mycophenolic Acid 11Cyclosporine 11Antilymphocyte Serum 10fludarabine 6Filgrastim 6peginterferon alfa-2a 5ruxolitinib 4Radiotherapy 4Methylprednisolone 4Melphalan 4Flow Cytometry 4Etoposide 4Decitabine 4Aspirin 4Stem Cell Transplantation 3Injections 3Cytogenetic Analysis 3Cytarabine 3Biopsy 3Azacitidine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3merphos 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Thrombocythemia, Essential × ruxolitinib × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04644211 2026-01-08

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Massachusetts General Hospital

Phase 2 Recruiting
60 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT02577926 2025-06-10

Ruxo-BEAT

RWTH Aachen University

Phase 2 Active not recruiting
207 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡